Free Trial
NASDAQ:MRKR

Marker Therapeutics Q3 2023 Earnings Report

Marker Therapeutics logo
$1.14 -0.09 (-7.32%)
Closing price 05/6/2025 03:59 PM Eastern
Extended Trading
$1.13 -0.01 (-0.53%)
As of 05/6/2025 06:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Marker Therapeutics EPS Results

Actual EPS
-$0.34
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Marker Therapeutics Revenue Results

Actual Revenue
$0.26 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Marker Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Thursday, November 9, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Marker Therapeutics' Q1 2025 earnings is scheduled for Wednesday, May 21, 2025, with a conference call scheduled on Wednesday, May 14, 2025 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Marker Therapeutics Earnings Headlines

Marker Therapeutics (MRKR) Receives a Buy from Canaccord Genuity
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
Marker Therapeutics reports FY24 EPS ($1.19) vs ($1.59) last year
See More Marker Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Marker Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Marker Therapeutics and other key companies, straight to your email.

About Marker Therapeutics

Marker Therapeutics (NASDAQ:MRKR), a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

View Marker Therapeutics Profile

More Earnings Resources from MarketBeat